Peter E. McKenna

Peter E. McKenna

Auto-generated profile, based on publicly available information

Peter E. McKenna

School of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
EMEmma McAlister
Emma McAlister
MKMelissa Kirkby
Melissa Kirkby
Juan Dominguez-RoblesJuan Dominguez-Robles
Juan Dominguez-Robles
Alejandro ParedesAlejandro Paredes
Alejandro Paredes
QAQonita Kurnia Anjani
Qonita Kurnia Anjani
Ryan DonnellyRyan Donnelly
Ryan Donnelly

1 June 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Alejandro ParedesAlejandro Paredes
Alejandro Paredes
IRInken K. Ramöller
Inken K. Ramöller
PMPeter E. McKenna
Peter E. McKenna
MAMarco T.A. Abbate
Marco T.A. Abbate
FVFabiana Volpe-Zanutto
Fabiana Volpe-Zanutto
Ryan DonnellyRyan Donnelly
Ryan Donnelly

22 June 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
PMPeter E. McKenna
Peter E. McKenna
MAMarco T. A. Abbate
Marco T. A. Abbate
Lalitkumar VoraLalitkumar Vora
Lalitkumar Vora
ASAkmal H. Sabri
Akmal H. Sabri
KPKe Peng
Ke Peng
Ryan DonnellyRyan Donnelly
Ryan Donnelly
Transdermal drug delivery is an alternative route of administration that offers avoidance of the associated drawbacks of orally and parenterally administered hydrophobics. However, owing to the extremely specific set of physicochemical characteristics required for passive transdermal drug permeation, the development of marketed transdermal products containing poorly soluble drugs has been severely limited. Microarray patches (MAPs) are a type of transdermal patch that differ from the traditional patch design due to the presence of tiny, micron-sized needles that permit enhanced drug permeation on their application surface. To date, MAPs have predominantly been used to deliver hydrophilic compounds. However, this work challenges this trend and focuses on the use of MAPs, in combination with commonly utilized solubility-enhancing techniques, to deliver the hydrophobic drug olanzapine (OLP) across the skin. Specifically, cyclodextrin (CD) complexation and particle size reduction were employed in tandem with hydrogel-forming and dissolving MAPs, respectively. In vivo experimentation using a female Sprague-Dawley rat model confirmed the successful delivery of OLP from hydrogel-forming MAPs (Cmax = 611.13 ± 153.34 ng/mL, Tmax = 2 h) and dissolving MAPs (Cmax = 690.56 ± 161.33 ng/mL, Tmax = 2 h) in a manner similar to that of oral therapy in terms of the rate and extent of drug absorption, as well as overall drug exposure and bioavailability. This work is the first reported use of polymeric MAPs in combination with the solubility-enhancing techniques of CD complexation and particle size reduction to successfully deliver the poorly soluble drug OLP via the transdermal route. Accordingly, this paper provides significant evidence to support an expansion of the library of molecules amenable to MAP-mediated drug delivery to include those that exhibit poor aqueous solubility.

21 April 2022 in British Journal of Pharmacy
Verified
Journal Article
Open access
CPCamila J. Picco
Camila J. Picco
PMPeter E. McKenna
Peter E. McKenna
Ryan DonnellyRyan Donnelly
Ryan Donnelly
Eneko LarrañetaEneko Larrañeta
Eneko Larrañeta
Implantable drug delivery systems are presented as a potential alternative to current treatments of chronic conditions. The aim of this work was to formulate a subcutaneous implantable device made with prefabricated poly(caprolactone) (PCL) cylinders, loaded with olanzapine (OLZ) as a model drug and cyclodextrin in a mass ratio of 1:1. The final formulation was characterized using optical microscopy, infrared spectroscopy, thermal analysis, and X-ray diffraction. The proposed device was successfully fabricated and demonstrated ability to control drug release for 60 days. With continued development, these novel implants could be an alternative to currently available treatments for schizophrenia.